Charles W. Francis

Charles W. Francis's AcademicInfluence.com Rankings

Charles W. Francis

Philosophy

#7719

World Rank

#10970

Historical Rank

Logic

#4758

World Rank

#6086

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Charles W. Francis's Degrees

Doctorate Medicine University of Medicine, Taunggyi

Why Is Charles W. Francis Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Charles W. Francis's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (1739)
Development and validation of a predictive model for chemotherapy-associated thrombosis. (2008) (1601)
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. (2013) (998)
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. (2007) (953)
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. (2020) (757)
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. (2015) (732)
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. (2009) (662)
A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. (1994) (498)
Thromboembolism in hospitalized neutropenic cancer patients. (2004) (447)
Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. (2000) (394)
Tissue Factor Expression, Angiogenesis, and Thrombosis in Pancreatic Cancer (2007) (354)
Ultrasound accelerates transport of recombinant tissue plasminogen activator into clots. (1995) (351)
Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. (2003) (325)
Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. (2008) (321)
Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients : A double-blind, randomized comparison (2000) (264)
Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. (2005) (255)
Enhancement of fibrinolysis in vitro by ultrasound. (1992) (234)
Two-step warfarin therapy. Prevention of postoperative venous thrombosis without excessive bleeding. (1983) (230)
Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty (2002) (219)
American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. (2019) (217)
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. (2009) (211)
Low-molecular-weight heparin prophylaxis using dalteparin Extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients : A double-blind, randomized comparison (2000) (207)
Thrombin activity of fibrin thrombi and soluble plasmic derivatives. (1983) (193)
Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. (1990) (192)
Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor‐2 (FGF‐2) (2007) (188)
Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes (2004) (177)
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. (2001) (175)
Cavitational mechanisms in ultrasound-accelerated thrombolysis at 1 MHz. (2000) (171)
Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after total hip replacement. (1992) (164)
Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (163)
Fibrin induces release of von Willebrand factor from endothelial cells. (1987) (161)
Prophylaxis for Thromboembolism in Hospitalized Medical Patients (2007) (158)
Enhancement of fibrinolysis with 40-kHz ultrasound. (1998) (157)
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. (2010) (154)
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double‐blind study (2003) (152)
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. (2001) (151)
Heparin Inhibition of Endothelial Cell Proliferation and Organization Is Dependent on Molecular Weight (2003) (145)
Characterization of ultrasound-potentiated fibrinolysis in vitro. (1993) (141)
Plasmic degradation of crosslinked fibrin. Characterization of new macromolecular soluble complexes and a model of their structure. (1980) (135)
Effect of 40-kHz ultrasound on acute thrombotic ischemia in a rabbit femoral artery thrombosis model: enhancement of thrombolysis and improvement in capillary muscle perfusion. (2000) (125)
Binding of tissue-plasminogen activator to fibrin: effect of ultrasound. (1998) (121)
Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. (2010) (117)
Increased resistance to plasmic degradation of fibrin with highly crosslinked alpha-polymer chains formed at high factor XIII concentrations. (1988) (112)
Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. (2017) (111)
Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes. (2004) (110)
Hemolysis in vivo from exposure to pulsed ultrasound. (1997) (109)
Ultrasound enhancement of thrombolysis and reperfusion in vitro. (1993) (108)
Platelets and Megakaryocytes Contain Functional Nuclear Factor-&kgr;B (2010) (106)
Peroxisome proliferator-activated receptor γ and retinoid X receptor transcription factors are released from activated human platelets and shed in microparticles (2007) (103)
Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation. (2001) (103)
Ultrasound Improves Tissue Perfusion in Ischemic Tissue through a Nitric Oxide Dependent Mechanism (2002) (101)
Characterization of ultrasound-potentiated fibrinolysis in vitro (1993) (101)
The platelet as an immune cell—CD40 ligand and transfusion immunomodulation (2009) (99)
Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. (2000) (94)
Response to plasma exchange and splenectomy in thrombotic thrombocytopenic purpura. A 10-year experience at a single institution. (1992) (94)
INCREASED PLASMA CONCENTRATION OF CROSSLINKED FIBRIN POLYMERS IN ACUTE MYOCARDIAL INFARCTION (1987) (92)
Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. (2007) (91)
15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes. (2008) (90)
FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis. (2006) (89)
Cell proliferation on fibrin: modulation by fibrinopeptide cleavage. (1995) (89)
Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection. (1986) (89)
Ultrasound‐Enhanced Thrombolysis (2001) (88)
Physiologic regulation and pathologic disorders of fibrinolysis. (1987) (85)
Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. (2005) (85)
A molecular model of plasmic degradation of crosslinked fibrin. (1982) (83)
Ultrasound enhancement of fibrinolysis at frequencies of 27 to 100 kHz. (2002) (83)
Flow through clots determines the rate and pattern of fibrinolysis. (1994) (82)
Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. (1980) (81)
Relation of Factor V Leiden Genotype to Risk for Acute Deep Venous Thrombosis after Joint Replacement Surgery (1998) (81)
Structural studies of fibrinolysis by electron microscopy. (1998) (81)
Venous thromboembolism in patients with diffuse large B-cell lymphoma (2006) (79)
Primary fibrinolysis during supraceliac aortic clamping. (1997) (77)
Plasminogen activator inhibitor-1 levels and polymorphisms. (2002) (75)
Endothelial cell spreading on fibrin requires fibrinopeptide B cleavage and amino acid residues 15-42 of the beta chain. (1992) (73)
Demonstration of a large molecular weight variant of the gamma chain of normal human plasma fibrinogen. (1980) (72)
Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires αvβ3 (2004) (71)
RAPID FORMATION OF LARGE MOLECULAR WEIGHT O-P0LYMERS IN CROSSLINKED FIBRIN INDUCED BY HIGH FACTOR XIII CONCENTRATIONS: ROLE OF PLATELET FACTOR XIII. (1987) (70)
Embolic complications of calf thrombosis following total hip arthroplasty. (1993) (69)
Nuclear Factor κB Protects against Host Cell Apoptosis during Rickettsia rickettsii Infection by Inhibiting Activation of Apical and Effector Caspases and Maintaining Mitochondrial Integrity (2003) (68)
A meta-analysis of anticoagulants as cancer treatment: Impact on survival and bleeding complications (2007) (67)
Ultrasound accelerates urokinase-induced thrombolysis and reperfusion. (1994) (67)
Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. (2000) (66)
Prevention of venous thrombosis after total hip arthroplasty. Antithrombin III and low-dose heparin compared with dextran 40. (1989) (66)
Relationship of the lytic state to successful reperfusion with standard- and low-dose intracoronary streptokinase. (1985) (65)
Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients. (2013) (64)
Ultrasound enhancement of rabbit femoral artery thrombolysis. (1997) (64)
Ultrasound energy improves myocardial perfusion in the presence of coronary occlusion. (2004) (62)
NF-kappaB activation suppresses host cell apoptosis during Rickettsia rickettsii infection via regulatory effects on intracellular localization or levels of apoptogenic and anti-apoptotic proteins. (2004) (62)
Randomized prospective study comparing routine versus selective use of sonography of the complete calf in patients with suspected deep venous thrombosis. (2003) (56)
Megakaryocyte and hepatocyte origins of human fibrinogen biosynthesis exhibit hepatocyte-specific expression of gamma chain-variant polypeptides. (1989) (56)
Platelet proteome changes associated with diabetes and during platelet storage for transfusion. (2009) (56)
Cancer-associated thrombosis. (2013) (55)
A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. (2016) (55)
Prevention of venous thromboembolism in hospitalized patients with cancer. (2009) (54)
Interleukin-1β but not IL-1α binds to fibrinogen and fibrin and has enhanced activity in the bound form (2004) (54)
Comparison of structures of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides. (1984) (53)
Risk prediction of cancer-associated thrombosis: Appraising the first decade and developing the future. (2018) (53)
LOWER RISK OF THROMBOEMBOLIC DISEASE AFTER TOTAL HIP REPLACEMENT WITH NON-CEMENTED THAN WITH CEMENTED PROSTHESES (1986) (51)
Acceleration of fibrinolysis by ultrasound in a rabbit ear model of small vessel injury. (1994) (51)
Prevention of venous thrombosis after total knee arthroplasty. Comparison of antithrombin III and low-dose heparin with dextran. (1990) (49)
Enzymatic Degradation of the Factor VIII-Von Willebrand Protein:A Unique Tryptic Fragment with Ristocetin Co-Factor Activity (1980) (49)
Determination of the topology of factor XIIIa-induced fibrin gamma-chain cross-links by electron microscopy of ligated fragments. (1993) (49)
Mediation of fibrin-induced release of von Willebrand factor from cultured endothelial cells by the fibrin beta chain. (1989) (49)
Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. (2001) (46)
Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique. (1985) (46)
Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential. (1992) (44)
Platelets and cancer-associated thrombosis. (2014) (43)
Long-term clinical observations and venous functional abnormalities after asymptomatic venous thrombosis following total hip or knee arthroplasty. (1988) (42)
Fibrinogen binding to human blood platelets: effect of gamma chain carboxyterminal structure and length. (1986) (41)
Effect of acoustic cavitation on platelets in the presence of an echo-contrast agent. (1998) (40)
Heparin-binding domain of fibrin mediates its binding to endothelial cells. (1996) (40)
Fibrinolytic therapy for venous thrombosis. (1991) (39)
Demonstration of in situ fibrin degradation in pathologic thrombi. (1984) (39)
Spreading of platelets on fibrin is mediated by the amino terminus of the beta chain including peptide beta 15-42. (1993) (38)
Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. (1990) (38)
Ultrasound and thrombolysis (2001) (38)
Fibrinogen regulates the expression of inflammatory chemokines through NF-κB activation of endothelial cells (2004) (36)
Binding of Tissue-Plasminogen Activator to Fibrin: Effect of Ultrasound (1998) (35)
Approach to pancytopenia: Diagnostic algorithm for clinical hematologists. (2018) (35)
Effects of lipids and lipid‐lowering therapy on hemostatic factors in patients with myocardial infarction (2004) (35)
Screening high-risk cancer patients for VTE: a prospective observational study. (2014) (33)
Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction. (1986) (33)
Degradation of cross-linked fibrin by human leukocyte proteases. (1986) (33)
Stimulation of endothelial cell proliferation by FGF-2 in the presence of fibrinogen requires alphavbeta3. (2004) (33)
Identification of a binding site on human FGF-2 for fibrinogen. (2004) (33)
Magnetic resonance imaging of blood and clots in vitro. (1990) (32)
Comparison of Native Prothrombin Antigen With the Prothrombin Time for Monitoring Oral Anticoagulant Prophylaxis (1993) (32)
Rapid Formation of Large Molecular Weight a-Polymers in Cross-Linked Fibrin Induced by High Factor XIII Concentrations (1987) (32)
Plasma and Platelet Fibrinogen Differ in γ Chain Content (1984) (32)
Heparin-Binding Domain of Fibrin Mediates Its Binding to Endothelial Cells (1996) (31)
Angioedema during therapy with recombinant tissue plasminogen activator. (1991) (30)
Neuropathologic findings in a Guillain-Barré patient with strokes after IVIg therapy. (2002) (30)
Detection of circulating crosslinked fibrin derivatives by a heat extraction-SDS gradient gel electrophoretic technique. (1979) (30)
Interleukin-1beta but not IL-1alpha binds to fibrinogen and fibrin and has enhanced activity in the bound form. (2004) (29)
Prevention of VTE in patients having major orthopedic surgery (2013) (29)
Fibrinogen binding potentiates FGF‐2 but not VEGF induced expression of u‐PA, u‐PAR, and PAI‐1 in endothelial cells (2004) (29)
Endothelial cell responses to fibrin mediated by FPB cleavage and the amino terminus of the beta chain. (1993) (29)
Thrombolytic therapy for acute transmural myocardial infarction. Intracoronary versus intravenous. (1984) (29)
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. (1992) (27)
Heparin induced thrombocytopenia and thrombosis in a tertiary care hospital. (2009) (27)
Structural and chromatographic heterogeneity of normal plasma fibrinogen associated with the presence of three gamma-chain types with distinct molecular weights. (1983) (27)
Diagnosis of femoropopliteal venous thrombosis with MR imaging: a comparison of four MR pulse sequences. (1990) (26)
Fiix-prothrombin time versus standard prothrombin time for monitoring of warfarin anticoagulation: a single centre, double-blind, randomised, non-inferiority trial. (2015) (26)
Reversal of multiorgan system dysfunction in sickle cell disease with plasma exchange (1997) (26)
Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993) (1994) (26)
Concepts of clot lysis. (1986) (26)
The C-terminal sequences of the gamma 57.5 chain of human fibrinogen constitute a plasmin sensitive epitope that is exposed in crosslinked fibrin. (1989) (25)
Relation of plasma D-dimer concentrations to coronary artery reperfusion before and after thrombolytic treatment in patients with acute myocardial infarction. (1989) (25)
Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis (2005) (25)
Calcium modulates plasmin cleavage of the fibrinogen D fragment γ chain N-terminus: mapping of monoclonal antibody J88B to a plasmin sensitive domain of the γ chain (1996) (24)
Purification and functional characterization of homodimeric gamma B-gamma B fibrinogen from rat plasma. (1993) (24)
Thrombotic thrombocytopenic purpura: Recovery after splenectomy associated with persistence of abnormally large von willebrand factor multimers (2006) (24)
New issues in oral anticoagulants. (2008) (23)
Effects of ionic and nonionic radiographic contrast agents on endothelial cells in vitro. (1992) (23)
Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time. (2012) (23)
Ximelagatran: a new oral anticoagulant. (2004) (23)
Plasma crosslinked fibrin polymers: quantitation based on tissue plasminogen activator conversion to D-dimer and measurement in normal and patients with acute thrombotic disorders. (1992) (22)
The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects (2007) (21)
Venous thromboembolism and all-cause mortality in cancer patients receiving chemotherapy (2008) (21)
15‐deoxy‐Δ12,14 prostaglandin J2‐induced heme oxygenase‐1 in megakaryocytes regulates thrombopoiesis (2009) (21)
Reactivity of Soluble Fibrin Assays with Plasmic Degradation Products of Fibrin and in Patients Receiving Fibrinolytic Therapy (1999) (21)
Factor XIII polymorphisms and venous thromboembolism. (2002) (21)
Prophylaxis of venous thrombosis following total hip and total knee replacement using antithrombin III and heparin. (1991) (20)
American Society of Clinical Oncology 2007 Clinical Practice Guideline Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. (2007) (20)
The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARgamma ligands. (2007) (20)
Plasmic degradation modulates activity of fibrinogen‐bound fibroblast growth factor‐2 (2003) (20)
Antithrombin III prophylaxis of venous thromboembolic disease after total hip or total knee replacement. (1989) (19)
Tissue Factor and VEGF Expression in Prostate Carcinoma: A Tissue Microarray Study (2009) (19)
Ultrasound Enhancement of Rabbit Femoral Artery Thrombolysis (1997) (19)
Cancer-associated thrombosis : new findings in translational science, prevention, and treatment (2007) (18)
Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non‐diabetic patients with coronary artery disease (2007) (18)
Purification of three gamma-chains with different molecular weights from normal human plasma fibrinogen. (1984) (18)
Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers. (1989) (17)
Low Molecular Weight Heparin Thromboprophylaxis in Ambulatory Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2009) (17)
Evaluation of mild bleeding disorders and easy bruising. (1994) (17)
Venous Thromboembolism Risk Model Predicts Early Progression and Overall Mortality in Cancer Patients Receiving Chemotherapy (2008) (17)
Multimer size dependence of von Willebrand factor binding to crosslinked or noncrosslinked fibrin. (1990) (17)
Atherosclerotic risk genotypes and recurrent coronary events after myocardial infarction. (2005) (16)
A Predictive Risk Score for Cancer-Associated Thrombosis: Role of Screening In A Prospective Study (2010) (16)
Purification and Functional Characterization of Homodimeric yB-yB Fibrinogen From Rat Plasma (15)
Carboxyl-terminal amino acid sequences of two variant forms of the gamma chain of human plasma fibrinogen. (1988) (15)
Isoprostane and isofuran lipid mediators accumulate in stored red blood cells and influence platelet function in vitro (2014) (15)
Endothelial Cell Activation by IL-1β in the Presence of Fibrinogen Requires αVβ3 (2005) (14)
Collaborative clinical trials. (2011) (14)
15-deoxy-12 , 14-PGJ 2 enhances platelet production from megakaryocytes (2008) (14)
Prevalence and clinical implications of heparin-associated false positive tests for serum fibrin(ogen) degradation products. (1986) (14)
Dalteparin Thromboprophylaxis in Cancer Patients at High Risk for Venous Thromboembolism: A Randomized Trial (2015) (14)
The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digests. (1989) (13)
Pioglitazone inhibits platelet function and potentiates the effects of aspirin: a prospective observation study. (2012) (13)
Protein S declines during winter respiratory infections (2003) (12)
Foxp3 Regulates Megakaryopoiesis and Platelet Function (2009) (11)
Heparin-induced thrombocytopenia. (1999) (11)
Plasmic degradation of fibrin rapidly decreases platelet adhesion and spreading. (1994) (10)
Low-molecular-weight heparin for venous thromboprophylaxis in ambulatory cancer patients: A meta-analysis. (2009) (10)
Dalteparin sodium for the long-term management of venous thromboembolism in cancer patients. The DALTECAN Study (2013) (9)
An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis. (1984) (9)
Antithrombin III/low-dose heparin in the prevention of deep-vein thrombosis after total knee arthroplasty. A preliminary report. (1989) (9)
Prolonged remission after life‐threatening gastrointestinal hemorrhage from coexistent angiodysplasia and acquired bleeding diathesis (1988) (8)
Fibrinogen‐ and Fibrin‐Degradation Products during Fibrinolytic Therapy a (1992) (8)
Warfarin: an historical perspective. (2008) (8)
Consultations on patients with venous or arterial diseases. (2003) (7)
Disseminated intravascular coagulation and status epilepticus (1998) (7)
Calcium modulates plasmin cleavage of the fibrinogen D fragment gamma chain N-terminus: mapping of monoclonal antibody J88B to a plasmin sensitive domain of the gamma chain. (1996) (7)
Low-Molecular-Weight Heparin Prophylaxis Using Dalteparin Extended Out-of-Hospital vs In-Hospital Warfarin / Out-of-Hospital Placebo in Hip Arthroplasty Patients (2000) (7)
9. Structural studies of fibrinolysis by electron microscopy (1998) (6)
Multimer size dependence of von Willebrand factor binding to crosslinked or noncrosslinked fibrin (1990) (6)
Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial (2017) (6)
Comparison of a low molecular weight heparin and warfarin in prevention of deep vein thrombosis after total hip arthroplasty (1997) (6)
Cerebrovascular ultrasound: Ultrasonic thrombolysis (2001) (5)
Comparison of a chromogenic prothrombin time with clotting prothrombin time in the assessment of clinical coagulation deficiencies. (1985) (5)
Monitoring of Therapy for Deep Vein Thrombosis Using Magnetic Resonance Imaging (1989) (5)
HETEROGENEITY OF NORMAL HUMAN FIBRINOGEN DUE TO TWO HIGH MOLECULAR WEIGHT VARIANT γ CHAINS (1983) (5)
A computerized prompt for thromboprophylaxis in hospitalized cancer patients. (2010) (5)
Endothelial cell activation by IL-1beta in the presence of fibrinogen requires alphavbeta3. (2005) (5)
Terminology for Fibrinogen γ-Chains Differing in Carboxyl Terminal Amino Acid Sequence (1989) (5)
A prediction model for chemotherapy-associated thrombocytopenia in cancer patients. (2006) (4)
Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation. (1986) (4)
Direct thrombin inhibitors for treatment of heparin induced thrombocytopenia, deep vein thrombosis and atrial fibrillation. (2005) (4)
Disorganized wound healing in fibrinogen-deficient mice (2001) (4)
Risk Score For Venous Thromboembolism (VTE) In Ambulatory Patients: Impact Of Cancer Type and Risk Score On VTE Incidence, Early Mortality and Progression-Free Survival (2013) (4)
Fffirin(ogen)-bound vascular endothelial growth factor stimulates endothelial cell proliferation (2000) (4)
Secretion of plasminogen activator by the human macrophage‐like cell line, GCT: separation from colony‐stimulating and erythropoiesis‐enhancing activities (1982) (3)
Preventing VTE in Outpatients With Cancer. (2012) (3)
Incidence of thromboembolic events in a prospective nationwide registry of cancer patients initiating systemic chemotherapy. (2004) (3)
Comprar Cancer-Associated Thrombosis: New Findings in Translational Science, Prevention, and Treatment | Charles W. Francis | 9781420047998 | Informa Healthcare (2007) (3)
Dose-Ranging Studies of Anisoylated Plasminogen Streptokinase Activator Complex (2012) (3)
Ultrasound increases fluid permeation in fibrin gels and reversibly disaggregates large fibers. (1996) (3)
Platelet Activation Following Exposure to Anti-ABO Antibodies-An In Vitro Study. (2011) (3)
Heterogeneity of normal human fibrinogen due to two high molecular weight variant gamma chains. (1983) (3)
Vaginal bleeding in early pregnancy and circulating markers of thrombin generation (2012) (3)
Contrast agents enhance biological effects in vivo. (1996) (2)
Evidence-Based Clinical Practice Guidelines American College of Chest Physicians and Prevention of Thrombosis , 9 th ed : Medical Patients : Antithrombotic Therapy Prevention of Thrombosis in Surgical and Approach to Outcome Measurement in the (2012) (2)
Tissue factor, angiogenesis and thrombosis in pancreatic cancer. (2006) (2)
Molecular weight dependent heparin inhibition of endothelial cell stimulation by FGF-2 and VEGF (2003) (2)
Overpressure reduces acceleration of thrombolysis due to ultrasound (1997) (2)
PGM Guidelines for Description of Criteria and Methods for Testing of Specificity of Assay Methods for Quantities in the Fibrinolytic System (2000) (2)
Anticardiolipin Antibodies and Recurrent Coronary Events (2000) (2)
Venous Thromboembolic Events in Patients with Diffuse Large B cell Non- Hodgkin’s Lymphoma. (2004) (2)
March 22 Highlight and Commentary (2005) (1)
Monitoring Warfarin with the Fiix-Prothrombin Time Improves Anticoagulation Stability and Long-Term Clinical Outcome. the Fiix-Trial (2014) (1)
Acceleration of thrombolysis with externally applied ultrasound (1995) (1)
Reply to Frequency, Risk Factors, and Trends for Venous Thromboembolism Among Hospitalized Cancer Patients (2008) (1)
Critical Role of Factors II and X During Coumarin Anticoagulation and Their Combined Measurement with a New Prothrombin Time Variant (Fiix-PT), (2011) (1)
Frequency, Risk Factors, and Trends for Venous Thromboembolism Among Hospitalized Cancer Patients. Authors' reply (2008) (1)
Thrombolytic therapy for arterial thrombosis. (1999) (1)
Comparison ofximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement (2003) (1)
Physiological Balance of Haemostasis and Bleeding (2012) (1)
Increasing risk for venous thromboembolism among hospitalized cancer patients (2007) (1)
A response to – There's madness in their methods (2013) (1)
Vascular Imaging in the Asymptomatic High‐risk Cancer Population (2021) (1)
Chapter 26 – Antithrombotic Agents (2007) (1)
The Effects of Anti-A and Anti-B On Platelet Function: An in Vitro Model of ABO Non-Identical Transfusion. (2009) (1)
Effects of ultrasound on binding of tissue plasminogen activator to fibrin. (1996) (1)
The Association Of Thrombin With Fibrin And Its Solubilization During Plasmic Digestion (1981) (1)
Management of concomitant factor VII deficiency and Factor V Leiden mutation (2017) (1)
Ximelagatran for prevention of venous thromboembolism in knee replacement (2004) (1)
Thrombolysis and Ultrasound (2002) (1)
Low intensity ultrasound increases endothelial cell nitric oxide synthase activity (2003) (0)
gamma B fibrinogen from rat plasma Purification and functional characterization of homodimeric gamma B (2011) (0)
MODULATION OF CELL PROLIFERATION ON FIBRIN 1803 from the peptide and DNA Sequence (2002) (0)
-PGJ2 enhances platelet production from megakaryocytes (2008) (0)
Book Review Hematologic and Oncologic Emergencies Edited by William R. Bell. 253 pp. New York, Churchill Livingstone, 1993. $65. 0-443-08871-3 (1994) (0)
Efficacy wnd Bleeding with Ximelagatran and Warfarin after TKR: Pooled Subgroup Analysis of 3 Phase III Trials. (2004) (0)
Victor J. Marder, M.D.: physician, scientist, founder, lover of the arts, teacher, leader (1934-2015). (2015) (0)
Correlation of cavitation‐induced damage to blood elements with passive acoustic detector output (1995) (0)
Arthroplastythe Prevention of Venous Thromboembolism After Total Knee Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin (2007) (0)
Development and validation of a predictive model for chemotherapy-associated thrombosis. Commentary (2008) (0)
Are Asymptomatic DVTs Relevant?: Response (2013) (0)
Potentiation of wheat germ agglutinin aggregation of platelets by von Willebrand protein and by a 116,000 molecular weight tryptic fragment. (1983) (0)
Rochester Center for Biomedical Ultrasound 2001 Annual Report Research Biophysical Bases of Pulsed Ultrasound Bioeffects (nci) and Ultrasound-induced Hyperthermic Teratogenicity (nichhd) 4 a K-space Method for Large-scale Models of Wave Propagation in Tissue 5 Time-shift Estimation and Focusing thro (0)
Pioglitazone Inhibits Platelet Function and Potentiates the Effects of Aspirin (2011) (0)
Abstract Oral communications I-5: Regulation of fibrinolysisUltrasound accelerates transport of recombinant tissue plasminogen activator (rt-PA) into clots (1994) (0)
Antithrombin III plus low-dose heparin in prophylaxis of deep vein thrombosis after total hip and total knee replacement (1990) (0)
THROMBOLYSIS Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction (2005) (0)
Structural Studies on the Functional Heterogeneity of (2016) (0)
Bleeding Indicators and Wound Complications with Ximelagatran and Warfarin after TKR: Findings from 3 Clinical Trials. (2004) (0)
New Thrombolytic Drugs (2001) (0)
OC-07 Enhanced thrombotic activity in association with increased circulating tissue factor activity in a mouse model of lymphoma (2007) (0)
Enhancement of fibrinolysis by low‐intensity c.w. ultrasound (1999) (0)
A Predictive Model for Chemotherapy-Associated Thrombosis Based on Findings from a Prospective Outpatient Registry. (2004) (0)
Terminology for fibrinogen gamma-chains differing in carboxyl terminal amino acid sequence. (1989) (0)
Incidence and Risk Factors for Thromboembolism in Patients with Hematologic Malignancies Undergoing Allogeneic and Autologous Stem Cell Transplantation. (2004) (0)
Tissue Factor-Related Biomarkers and Prediction of Cancer-Associated VTE: Correlative Analyses of the Phacs Trial (2017) (0)
Gender Differences during Long-Term Warfarin Anticoagulation in Patients with Atrial Fibrillation Monitored with Fiix-Prothrombin Time or Prothrombin Time. the Fiix Trial (2015) (0)
Thrombocytosis Increases the Risk of Chemotherapy-Associated Thrombosis. (2004) (0)
agonists blunt platelet release of CD40 ligand and thromboxanes γ PPAR , and γ Human bone marrow megakaryocytes and platelets express PPAR (2013) (0)
50. Calcium modulates plasmin cleavage of the fibrinogen D fragment G chain N-terminus: mapping of monoclonal antibodies to plasmin sensitive domains of the G chain (1996) (0)
Thrombolysis , Reperfusion and Survival After Myocardial Infarcts Low-Dose Dobutamine Echocardiography Detects Reversible Dysfunction After Thrombolytic Therapy of Acute Myocardial Infarction (2005) (0)
Venous Thromboembolism andAnticoagulation (2008) (0)
Abstract 3969: Favorable Effects of Pioglitazone on Fasting and Postprandial Levels of Lipid and Hemostatic Variables in Overweight Non-diabetic Patients with Coronary Artery Disease (2006) (0)
Two-step warfarin therapy for the prophylaxis of venous thrombosis after elective surgery. (1987) (0)
Thromboembolism and Clinically Relevant Bleeding in Relation to Warfarin Anticoagulation Variability in Patients Monitored with Either Fiix-Prothrombin Time or Quick-Prothrombin Time. the Fiix-Trial (2015) (0)
Role of Soluble Crosslinked Fibrin Polymers (2005) (0)
Interleukin-1 (cid:1) but not IL-1 (cid:2) binds to ﬁbrinogen and ﬁbrin and has enhanced activity in the bound form (2004) (0)
External pneumatic compression stockings: Inadequate prophylexis of proximal DVT following total hip arthroplasty (1993) (0)
MYOCARDIAL INFARCTION Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction (0)
High Incidence of Thromboembolic Complications and PF4 Positivity in Patients with Ventricular Assist Devices. (2006) (0)
Management of Patients With Deep Venous Thrombosis-Reply (1994) (0)
Dalteparin vs Warfarin in Hip Arthroplasty Patients—Reply (2001) (0)
Identification of Crosslinked Fibrin Degradation Products in Plasma of Patients During Fibrinolytic Therapy Using a Heat Extraction/SDS-Polyacrylamide Gradient Gel Electrophoretic Technique (1979) (0)
#661 Apoptotic gene protein expression in low grade versus high grade pediatric gliomas (1998) (0)
Acceleration of thrombolysis by ultrasound in two rabbit models. (1996) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Charles W. Francis?

Charles W. Francis is affiliated with the following schools: